NEW YORK (TheStreet
) -- Today's earnings scorecard features nine companies that reported quarterly results Thursday and Friday. I previewed these buy-rated stocks Wednesday in Dollar Tree, Gap, Big Lots Earnings Lead Buy Rated Retailers
. Three of these stocks beat earnings per share estimates, two matched estimates and four missed estimates. Two stocks were sent to the investor woodshed while one had a moon-shot.
Abercrombie & Fitch ($37.70) missed EPS estimates by 12 cents earning 16 cents a share. The stock was sent to the investor woodshed trading down from $46.80 at the Wednesday close to as low as $36.90 on Thursday, which was a test of my quarterly value level, now a pivot at $37.84. This severe decline in the stock price was enough for ValuEngine to upgrade the retailer to strong buy from buy, but I do not have a value level at this time. This week's risky level is $49.24.
Ann ($34.26) beat EPS estimates by 11 cents premarket on Friday earning 76 cents a share. The stock stayed above its 200-day SMA at $31.46 and maintains its buy rating. My annual value level is $30.07 with a quarterly pivot at $33.62 and semiannual risky level at $40.61.
Aeropostale ($8.71) missed EPS estimates by 10 cents reporting a loss of 34 cents a share. The stock had been sliding lower since Aug. 1 and closed Thursday at $10.98 before taking the trip to the investor woodshed Friday down to a new multi-year low at $8.59. This weakness resulted in an upgrade to strong buy fro buy according to ValuEngine. My quarterly value level is $6.11 with a weekly risky level at $11.71.
Buckle ($52.14) matched EPS estimates earning 52 cents a share. The stock slipped to $49.87 on Thursday testing my semiannual value level, now a pivot at $50.74. The buy-rated stock stayed above its 200-day SMA at $49.29. My quarterly value level is $47.87 with the semiannual pivot at $50.74 and semiannual risky level at $56.19.
Dollar Tree ($54.12) missed EPS estimates by a penny earning 56 cents a share. Improved operating margins help the buy-rated discount retailer to trade to a high of $54.92 on Thursday. My semiannual pivot at $52.56 proved to be a magnet after a post-earnings low of $51.70. My monthly pivot is $53.35 with a weekly risky level at $55.38.
Foot Locker ($33.02) missed EPS estimates by 2 cents earning 46 cents a share premarket on Friday. The buy-rated stock failed to hold its 200-day SMA at $34.34 and traded to a day's low at $32.50. I do not have a value level and the 2013 low is $31.12 set on the first trading day of the year. My monthly pivot is $33.38 with a weekly risky level at $35.55.
Gamestop ($52.38) beat EPS estimates by 5 cents earning 9 cents a share premarket on Thursday. The stock opened with a moon-shot to a new multi-year high at $56.08. This strength caused the stock to be downgraded to hold from buy and hence Friday's close was down 7.7% from the high. My monthly value level is $42.53 with a weekly pivot at $52.55, which was a magnet on Monday.
Gap ($41.43) matched EPS estimates earning 64 cents a share after the close on Thursday. The buy-rated stock traded slightly higher on Friday, but closed slightly lower. My semiannual value level is $37.17 with monthly and quarterly pivots at $42.01 and $42.78 and a weekly risky level at $46.39.
Children's Place ($55.30) beat EPS estimates by 12 cents reporting a better than expected loss of 42 cents a share premarket on Thursday. The buy-rated stock popped from a Wednesday close at $51.40 to a fresh 2013 high at $58.88. The stock tested my monthly value level at $51.29 at the Wednesday pre-earnings low. My annual and quarterly pivots are $57.18 and $57.70 semiannual risky levels at $67.12 and $68.68.
At the time of publication the author held no positions in any of the stocks mentioned.
This article is commentary by an independent contributor, separate from TheStreet's regular news coverage.
EXCLUSIVE OFFER: See inside Jim Cramer’s multi-million dollar charitable trust portfolio to see the stocks he thinks could be potentially HUGE winners. Click here to see his holdings for FREE.
- Investment & Company Information